Fcγ Receptors in Solid Organ Transplantation

Current Transplantation Reports

Volumn 3, Issue 4, 2016, Pages 284-293

  Castro Dopico, Tomas ^a   Clatworthy, Menna R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Antibodies; Antibody mediated rejection; Fc receptors; IgG; Infection; Single nucleotide polymorphisms

Indexed keywords

EID: 85014414678     PISSN: None     EISSN: 21963029     Source Type: Journal    
DOI: 10.1007/s40472-016-0116-7     Document Type: Article

References (108)

1. Nimmerjahn F, Ravetch JV. Fcg receptors as regulators of immunity. Adv Immunol. 2007;96:179–204. DOI: 10.1016/S0065-2776(07)96005-8
2. Pincetic A et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol. 2014;15(8):707–16. DOI: 10.1038/ni.2939
3. Clatworthy MR, Smith KG. B cells in glomerulonephritis: focus on lupus nephritis. Semin Immunopathol. 2007;29(4):337–53. DOI: 10.1007/s00281-007-0092-1
4. Cui Z, Zhao MH. Advances in human antiglomerular basement membrane disease. Nat Rev Nephrol. 2011;7(12):697–705. DOI: 10.1038/nrneph.2011.89
5. Loupy A, Hill GS, Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol. 2012;8(6):348–57. DOI: 10.1038/nrneph.2012.81
6. Loupy A, Jordan SC. Transplantation: donor-specific HLA antibodies and renal allograft failure. Nat Rev Nephrol. 2013;9(3):130–1. DOI: 10.1038/nrneph.2013.18
7. Jolly EC et al. Preformed donor HLA-DP-specific antibodies mediate acute and chronic antibody-mediated rejection following renal transplantation. Am J Transplant. 2012;12(10):2845–8. DOI: 10.1111/j.1600-6143.2012.04172.x
8. Loupy A et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013;369(13):1215–26. DOI: 10.1056/NEJMoa1302506
9. Hidalgo LG et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant. 2009;9(11):2532–41. DOI: 10.1111/j.1600-6143.2009.02800.x
10. Einecke G et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009;9(11):2520–31. DOI: 10.1111/j.1600-6143.2009.02799.x
11. Sis B, Halloran PF. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant. 2010;15(1):42–8. DOI: 10.1097/MOT.0b013e3283352a50
12. Haas M et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14(2):272–83. DOI: 10.1111/ajt.12590
13. Spiegelberg HL. Biological role of different antibody classes. Int Arch Allergy Appl Immunol. 1989;90(Suppl 1):22–7. DOI: 10.1159/000235071
14. Jindra PT et al. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol. 2008;180(4):2357–66. DOI: 10.4049/jimmunol.180.4.2357
15. Clatworthy, M.R., Fcy Receptor polymorphisms and susceptibility to infection, in Antibody Fc. Linking adaptive and innate immunity, M.E.N. Ackerman, F., Editor. 2014, Academic Press, Elsevier. p. 217–238.
16. Clynes RA et al. Inhibitory Fcg receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6(4):443–6. DOI: 10.1038/74704
17. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A. 1995;92(3):821–5. DOI: 10.1073/pnas.92.3.821
18. Zhou X et al. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21(1):108–14. DOI: 10.1161/01.ATV.21.1.108
19. Kiener PA et al. Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler Thromb Vasc Biol. 1995;15(7):990–9. DOI: 10.1161/01.ATV.15.7.990
20. Smith KGC, Clatworthy MR. FcgRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol. 2010;10(5):328–43. DOI: 10.1038/nri2762
21. Bharadwaj D et al, The major receptor for C-reactive protein on leukocytes is fcgamma receptor II. J Exp Med. 1999;190(4):585–90. Demonstration that FcγRs can not only bind IgG but can also bind acute phase response proteins, broadening their potential role in both inflammation and defence against infection.
22. Bharadwaj D et al. Serum amyloid P component binds to Fc gamma receptors and opsonizes particles for phagocytosis. J Immunol. 2001;166(11):6735–41. DOI: 10.4049/jimmunol.166.11.6735
23. Pricop L et al. Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J Immunol. 2001;166(1):531–7. DOI: 10.4049/jimmunol.166.1.531
24. Liu Y et al. Cytokine-mediated regulation of activating and inhibitory Fc gamma receptors in human monocytes. J Leukoc Biol. 2005;77(5):767–76. DOI: 10.1189/jlb.0904532
25. Anthony RM et al. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 2011;475(7354):110–3 Demonstration of the importance of, and one of the mechansims by which, IgG sialylation can promote immunoregulation by ligating DC-SIGN and inducing IL33 production to enhance basophil IL4 secretion, culminating in the upregulation of FcγRIIB on effector macrophages.
26. Boruchov AM et al. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest. 2005;115(10):2914–23. DOI: 10.1172/JCI24772
27. Willcocks LC, Smith KG, Clatworthy MR. Low-affinity Fcg receptors, autoimmunity and infection. Expert Rev Mol Med. 2009;11:e24. DOI: 10.1017/S1462399409001161
28. Shields RL et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgRIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277(30):26733–40. DOI: 10.1074/jbc.M202069200
29. Ferrara C et al. The carbohydrate at FcgRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem. 2006;281(8):5032–6. DOI: 10.1074/jbc.M510171200
30. Arnold JN et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21–50. DOI: 10.1146/annurev.immunol.25.022106.141702
31. Lux A, Nimmerjahn F. Impact of differential glycosylation on IgG activity. Adv Exp Med Biol. 2011;780:113–24. DOI: 10.1007/978-1-4419-5632-3_10
32. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 2005;310(5753):1510–2. DOI: 10.1126/science.1118948
33. Vuckovic, F., et al., Systemic lupus erythematosus associates with the decreased immunosuppressive potential of the IgG glycome. Arthritis Rheumatol, 2015.
34. Albrecht S et al. Glycosylation as a marker for inflammatory arthritis. Cancer Biomark. 2014;14(1):17–28.
35. Daeron M. Fc receptor biology. Annu Rev Immunol. 1997;15:203–34. DOI: 10.1146/annurev.immunol.15.1.203
36. Ono M et al. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FcgRIIB. Nature. 1996;383(6597):263–6. DOI: 10.1038/383263a0
37. Pan LF, Kreisle RA, Shi YD. Detection of Fcg receptors on human endothelial cells stimulated with cytokines tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma). Clin Exp Immunol. 1998;112(3):533–8. DOI: 10.1046/j.1365-2249.1998.00597.x
38. van Mirre E et al. Neutrophil responsiveness to IgG, as determined by fixed ratios of mRNA levels for activating and inhibitory FcgRII (CD32), is stable over time and unaffected by cytokines. Blood. 2006;108(2):584–90. DOI: 10.1182/blood-2005-12-4997
39. Willcocks LC et al. Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. J Exp Med. 2008;205(7):1573–82. First investigation of a human subject with FcγRIIIB-deficiency demonstrating the importance of this receptor in immune complex uptake by neutrophils.
40. Ericson JA et al. Gene expression during the generation and activation of mouse neutrophils: implication of novel functional and regulatory pathways. PLoS One. 2014;9(10):e108553. DOI: 10.1371/journal.pone.0108553
41. Rosales C, Brown EJ. Signal transduction by neutrophil immunoglobulin G Fc receptors. Dissociation of intracytoplasmic calcium concentration rise from inositol 1,4,5-trisphosphate. J Biol Chem. 1992;267(8):5265–71.
42. Zhou MJ, Brown EJ. CR3 (Mac-1, alpha M beta 2, CD11b/CD18) and Fc gamma RIII cooperate in generation of a neutrophil respiratory burst: requirement for Fc gamma RIII and tyrosine phosphorylation. J Cell Biol. 1994;125(6):1407–16. DOI: 10.1083/jcb.125.6.1407
43. Coxon A et al. FcyRIII mediates neutrophil recruitment to immune complexes: a mechanism for neutrophil accumulation in immune-mediated inflammation. Immunity. 2001;14(6):693–704. DOI: 10.1016/S1074-7613(01)00150-9
44. Kessenbrock K et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15(6):623–5. DOI: 10.1038/nm.1959
45. Mayadas TN, Tsokos GC, Tsuboi N. Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury. Circulation. 2009;120(20):2012–24. DOI: 10.1161/CIRCULATIONAHA.108.771170
46. Sur Chowdhury C et al. Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility. Arthritis Res Ther. 2014;16(3):R122. DOI: 10.1186/ar4579
47. Guilliams M et al. The function of Fcg receptors in dendritic cells and macrophages. Nat Rev Immunol. 2014;14(2):94–108. DOI: 10.1038/nri3582
48. Clynes R et al. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med. 1999;189(1):179–85. DOI: 10.1084/jem.189.1.179
49. Yuasa T et al. Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. J Exp Med. 1999;189(1):187–94. DOI: 10.1084/jem.189.1.187
50. Clatworthy MR, Smith KG. FcgRIIb balances efficient pathogen clearance and the cytokine-mediated consequences of sepsis. J Exp Med. 2004;199(5):717–23. DOI: 10.1084/jem.20032197
51. Brownlie RJ et al. Distinct cell-specific control of autoimmunity and infection by FcgRIIb. J Exp Med. 2008;205(4):883–95. DOI: 10.1084/jem.20072565
52. Regnault A et al. Fcg receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med. 1999;189(2):371–80. DOI: 10.1084/jem.189.2.371
53. de Jong JM et al. Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+ T cells upon immune-complex uptake in vivo. Immunology. 2006;119(4).
54. Clatworthy, M.R., et al., Immune complexes stimulate CCR7-dependent dendritic cell migration to lymph nodes. Nat Med, 2014. 20(12): p. 1458–63. First demonstration that FcγR cross-linking by IC can alter the migratory behaviour of DCs.
55. Dhodapkar KM et al. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci U S A. 2005;102(8):2910–5. DOI: 10.1073/pnas.0500014102
56. Dhodapkar KM et al. Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med. 2007;204(6):1359–69. DOI: 10.1084/jem.20062545
57. Titus JA et al. Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J Immunol. 1987;139(9):3153–8.
58. Metes D et al. Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the FcgammaRIIC gene. Blood. 1998;91(7):2369–80.
59. Xiang Z et al. FcgRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol. 2007;8(4):419–29. DOI: 10.1038/ni1440
60. Bian H et al. Anti-HLA antibody ligation to HLA class I molecules expressed by endothelial cells stimulates tyrosine phosphorylation, inositol phosphate generation, and proliferation. Hum Immunol. 1997;53(1):90–7. DOI: 10.1016/S0198-8859(96)00272-8
61. Jindra PT et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation. 2006;82(1 Suppl):S33–5. DOI: 10.1097/01.tp.0000231447.34240.3c
62. Valenzuela NM et al. Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcgRIIa polymorphisms. Am J Transplant. 2015;15(6):1502–18. DOI: 10.1111/ajt.13174
63. Devaraj S, Du Clos TW, Jialal I. Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol. 2005;25(7):1359–63. DOI: 10.1161/01.ATV.0000168573.10844.ae
64. Sundgren NC et al. IgG receptor FcgammaRIIB plays a key role in obesity-induced hypertension. Hypertension. 2015;65(2):456–62. DOI: 10.1161/HYPERTENSIONAHA.114.04670
65. Suwanichkul A, Wenderfer SE. Differential expression of functional Fc-receptors and additional immune complex receptors on mouse kidney cells. Mol Immunol. 2013;56(4):369–79. DOI: 10.1016/j.molimm.2013.05.219
66. Callaghan CJ et al. Regulation of allograft survival by inhibitory FcgammaRIIb signaling. J Immunol. 2012;189(12):5694–702. This study demonstrates the importance of inhibitory FcγRIIB in a murine cardiac allograft model through the suppression of alloantibody generation. DOI: 10.4049/jimmunol.1202084
67. Sharp PE et al. FcgRIIb on myeloid cells and intrinsic renal cells rather than B cells protects from nephrotoxic nephritis. J Immunol. 2013;190(1):340–8. DOI: 10.4049/jimmunol.1202250
68. Magil AB, Tinckam K. Monocytes and peritubular capillary C4d deposition in acute renal allograft rejection. Kidney Int. 2003;63(5):1888–93. DOI: 10.1046/j.1523-1755.2003.00921.x
69. Tinckam KJ, Djurdjev O, Magil AB. Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status. Kidney Int. 2005;68(4):1866–74. DOI: 10.1111/j.1523-1755.2005.00606.x
70. Xu L et al. Increased macrophage density of cardiac allograft biopsies is associated with antibody-mediated rejection and alloantibodies to HLA antigens. Clin Transpl. 2014;28(5):554–60. DOI: 10.1111/ctr.12348
71. Hidalgo LG et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant. 2010;10(8):1812–22. DOI: 10.1111/j.1600-6143.2010.03201.x
72. Hidalgo LG et al. Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. Am J Transplant. 2012;12(5):1180–91. DOI: 10.1111/j.1600-6143.2011.03970.x
73. Kerjaschki D et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol. 2004;15(3):603–12. DOI: 10.1097/01.ASN.0000113316.52371.2E
74. Clatworthy MR et al. FcgRIIb inhibits immune complex-induced VEGF-A production and intranodal lymphangiogenesis. Proc Natl Acad Sci U S A. 2014;111(50):17971–6. DOI: 10.1073/pnas.1413915111
75. Venner JM et al. The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors. Am J Transplant. 2015;15(5):1336–48. This paper demonstrates an association between ABMR and FcγR-associated transcripts in renal transplant biopsies, implicating ADCC as a driver of allograft rejection. DOI: 10.1111/ajt.13115
76. Pawlik A et al. The correlation between FcgRIIA polymorphism and renal allograft survival. Transplant Proc. 2002;34(8):3138–9. DOI: 10.1016/S0041-1345(02)03584-4
77. Pawlik A et al. The FcgRIIa polymorphism in patients with chronic kidney graft rejection. Transplant Proc. 2004;36(5):1311–3. DOI: 10.1016/j.transproceed.2004.05.076
78. Yuan FF et al. Association of Fcg receptor IIA polymorphisms with acute renal-allograft rejection. Transplantation. 2004;78(5):766–9. DOI: 10.1097/01.TP.0000132560.77496.CB
79. Ozkayin N, Mir S, Afig B. The role of fcgamma receptor gene polymorphism in pediatric renal transplant rejections. Transplant Proc. 2008;40(10):3367–74. DOI: 10.1016/j.transproceed.2008.08.137
80. Arnold ML et al. Association of a coding polymorphism in Fcg receptor 2A and graft survival in re-transplant candidates. Hum Immunol. 2015;76(10):759–64. DOI: 10.1016/j.humimm.2015.09.034
81. Floto RA et al. Loss of function of a lupus-associated FcgRIIb polymorphism through exclusion from lipid rafts. Nat Med. 2005;11(10):1056–8. First demonstration of the mechanism by which a transmembrane domain amino acid substitution leads to a failure of inhibitory function of FcγRIIB, providing an explanation for the association of this SNP with SLE susceptibility.
82. Kono H et al. FcgRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum Mol Genet. 2005;14(19):2881–92. DOI: 10.1093/hmg/ddi320
83. Willcocks LC et al. A defunctioning polymorphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus erythematosus. Proc Natl Acad Sci U S A. 2010;107(17):7881–5. DOI: 10.1073/pnas.0915133107
84. Clatworthy MR et al. Systemic lupus erythematosus-associated defects in the inhibitory receptor FcgRIIb reduce susceptibility to malaria. Proc Natl Acad Sci U S A. 2007;104(17):7169–74. DOI: 10.1073/pnas.0608889104
85. Clatworthy MR et al. Defunctioning polymorphism in the immunoglobulin G inhibitory receptor (FcgRIIB-T/T232) does not impact on kidney transplant or recipient survival. Transplantation. 2014;98(3):285–91. DOI: 10.1097/TP.0000000000000287
86. Bournazos S, DiLillo DJ, Ravetch JV. The role of Fc-FcgR interactions in IgG-mediated microbial neutralization. J Exp Med. 2015;212(9):1361–9. DOI: 10.1084/jem.20151267
87. Gjertsson I, Kleinau S, Tarkowski A. The impact of Fcγ receptors on Staphylococcus aureus infection. Microb Pathog. 2002;33(4):145–52. DOI: 10.1016/S0882-4010(02)90524-3
88. Maglione PJ et al. Fcγ receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J Immunol. 2008;180(5):3329–38. DOI: 10.4049/jimmunol.180.5.3329
89. Da Silva DM et al. Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol. 2007;178(12):7587–97. DOI: 10.4049/jimmunol.178.12.7587
90. Shimizu S et al. Fc-g receptor polymorphisms predispose patients to infectious complications after liver transplantation. Am J Transplant. 2016;16(2):625–33. The authors identify SNPs in FcγR genes as risk factors for infection and mortality in patients following liver transplantation, attributed to diminished CRP binding. DOI: 10.1111/ajt.13492
91. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcg receptors on dendritic cells. J Exp Med. 2002;195(12):1653–9. DOI: 10.1084/jem.20020338
92. Schuurhuis DH et al. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol. 2006;176(8):4573–80. DOI: 10.4049/jimmunol.176.8.4573
93. Carmi Y et al. Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature. 2015;521(7550):99–104. Elegant demonstration of the potential of IgG to promote an immune response that inhibits a variety of different tumour types in vivo, via FcγR-dependent DC activation.
94. Diamantopoulos PT et al. Correlation of FcgRIIA polymorphisms with latent Epstein-Barr virus infection and latent membrane protein 1 expression in patients with low grade B-cell lymphomas. Leuk Lymphoma. 2013;54(9):2030–4. DOI: 10.3109/10428194.2012.762512
95. Ghesquieres H et al. FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status. Leuk Lymphoma. 2013;54(11):2571–3. DOI: 10.3109/10428194.2013.796048
96. Mellor JD et al. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol. 2013;6:1. DOI: 10.1186/1756-8722-6-1
97. Nicoletti A et al. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest. 1998;102(5):910–8. DOI: 10.1172/JCI119892
98. Yuan Z et al. Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion. Am J Physiol Heart Circ Physiol. 2003;285(2):H899–906. DOI: 10.1152/ajpheart.00926.2002
99. Okabe TA et al. Effects of late administration of immunoglobulin on experimental atherosclerosis in apolipoprotein E-deficient mice. Circ J. 2005;69(12):1543–6. DOI: 10.1253/circj.69.1543
100. Burut DF, Karim Y, Ferns GA. The role of immune complexes in atherogenesis. Angiology. 2010;61(7):679–89. DOI: 10.1177/0003319710366124
101. Ait-Oufella H et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med. 2010;207(8):1579–87. DOI: 10.1084/jem.20100155
102. Hernandez-Vargas P et al. Fcg receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice. Circ Res. 2006;99(11):1188–96. DOI: 10.1161/01.RES.0000250556.07796.6c
103. Kishimoto C. A novel approach to the suppression of atherosclerosis by Fcg receptor blockade. Circ Res. 2006;99(11):1154–5. DOI: 10.1161/01.RES.0000251794.69345.0c
104. Kelly JA et al. Inhibition of arterial lesion progression in CD16-deficient mice: evidence for altered immunity and the role of IL-10. Cardiovasc Res. 2010;85(1):224–31. DOI: 10.1093/cvr/cvp300
105. Ng HP, Burris RL, Nagarajan S. Attenuated atherosclerotic lesions in apoE-Fcg-chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T cells. J Immunol. 2011;187(11):6082–93. DOI: 10.4049/jimmunol.1004133
106. Zhao M et al. FcgRIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient mice. J Immunol. 2010;184(5):2253–60. DOI: 10.4049/jimmunol.0902654
107. Mendez-Fernandez YV et al. The inhibitory FcgRIIb modulates the inflammatory response and influences atherosclerosis in male apoE(−/−) mice. Atherosclerosis. 2010;214(1):73–80. DOI: 10.1016/j.atherosclerosis.2010.10.018
108. Gavasso S et al. Fcg receptor IIIA polymorphism as a risk-factor for coronary artery disease. Atherosclerosis. 2005;180(2):277–82. DOI: 10.1016/j.atherosclerosis.2004.12.011